title: Transmucosal delivery systems for calcitonin: a review.
abstract: The commercial availability of peptides and proteins and their advantages as therapeutic agents have been the basis for tremendous efforts in designing delivery systems for such agents. The protection of these agents from biological fluids and physiological interactions is crucial for the treatment efficacy. One such agent is salmon calcitonin, a 32 amino-acid polypeptide hormone used in the treatment of bone diseases such as Paget's disease, hypercalcemia and osteoporosis. Researchers have studied different routes to deliver salmon calcitonin more effectively, including nasal, oral, vaginal and rectal delivery. These systems are designed to protect the polypeptide from the biological barriers that each delivery route imposes. Oil-based and polymer-based delivery systems are discussed.
authors.affiliation: Biomaterials and Drug Delivery Laboratories, School of Chemical Engineering, Purdue University, West Lafayette, IN 47906-1283, USA.
authors.forename: M
authors.initials: M
authors.lastname: Torres-Lugo
authors.forename: N A
authors.initials: NA
authors.lastname: Peppas
mesh_terms: D000180:Acrylic Resins / Q000008:administration & dosage / Q000493:pharmacokinetics; D000281:Administration, Intranasal; D000282:Administration, Intravaginal; D000284:Administration, Oral; D000595:Amino Acid Sequence; D000818:Animals; D001673:Biodegradation, Environmental; D001682:Biological Availability; D001704:Biopolymers; D002116:Calcitonin / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D003487:Cyanoacrylates / Q000008:administration & dosage / Q000493:pharmacokinetics; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004339:Drug Compounding; D004659:Enbucrilate; D005260:Female; D006801:Humans; D020100:Hydrogels / Q000008:administration & dosage / Q000493:pharmacokinetics; D019344:Lactic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics; D008297:Male; D008969:Molecular Sequence Data; D009092:Mucous Membrane / Q000378:metabolism*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000493:pharmacokinetics; D011100:Polyglycolic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000008:administration & dosage / Q000493:pharmacokinetics; D011109:Polymethacrylic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics; D011137:Polystyrenes / Q000008:administration & dosage / Q000493:pharmacokinetics; D012474:Salmon; D013552:Swine; D000099166:Polyacrylamides
chemical_list: D000180:Acrylic Resins; D001704:Biopolymers; D002116:Calcitonin; D003487:Cyanoacrylates; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004659:Enbucrilate; D020100:Hydrogels; D019344:Lactic Acid; D011092:Polyethylene Glycols; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D011109:Polymethacrylic Acids; D011137:Polystyrenes; D000099166:Polyacrylamides; C099679:poly(methacrylic acid-ethylene glycol)